New Anticoagulants in Clinical Practice

• Authors: Leszek Czerchawski , Wojciech Witkiewicz
• Languages of publication: EN

Abstracts

EN

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2009
• Volume: 81
• Issue: 6
• Pages: 287-291

Dates

published

1 - 6 - 2009

online

1 - 7 - 2009

Contributors

author

Leszek Czerchawski

• Department of General and Vascular Surgery, Regional Specialized Hospital, Wrocław, Research and Development Centre Kierownik

author

Wojciech Witkiewicz

• Department of General and Vascular Surgery, Regional Specialized Hospital, Wrocław, Research and Development Centre Kierownik

References

• Walenga JM, Jeske WP, Samama MM et al.: Fondaparinux: a synthetic heparin pentasacharide as a new antithrombotic agent. Expert Opin Invest Drugs 2002; 11: 397--407.
• Turpie AG, Bauer AK, Eriksson BI, Lassen MR: Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833--40.
• Bijsterveld NR, Moons AH, Boekholdt SM et al.: Ability of recombinant factor VIIa to reverse anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550--54.
• The van Gogh Investigators. Idraparinux versus Standard Therapy for Venous Thromboembolic Disease. 2007; 357: 1094--1104.
• Kapalan KL, Francis CW: Direct thrombin inhibitors. Semin Hemotol 2002; 39: 187--96.
• Lin H, Fleming NW, Moor PG: Anticoagulation for patients with heparin induced thrombocytopenia using recombinant hirudin during cardiopulmonary by-pass. J Clin Anesth 2002; 14: 452--55.
• Turpie AGG, Gallus AS, Hoek JA: Prevention of Deep Vein Thrombosis after Total Hip Replacement. N Engl J Med 2001; 344: 619--25.
• Buller HR, Ander TC, Davidson B et al.: Idraparinux versus standard therapy for venous thromboembolic disease. N Engel J Med 2007; 357: 1094--1104.
• Buller HR, Ander TC, Davidson B et al.: Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 110--12.
• Greinacher A, Volpel H, Janssens V et al.: For the HIT investigators group. Recombinant hirudin (lepirudin) provide safe and effective anticoagulation in patients with heparin induced thrombocytopenia -- a prospective study. Circulation 1999; 99: 73--80.
• Greinacher A, Eichler P, Lubenow N et al.: Heparin induced thromboembolic complications: meta analysis of 2 prospective trials to asses the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846--51.
• Czerchawski L: Podstawy profilaktyki i leczenia zakrzepic. Akademia Medyczna im. Piastów Śląskich we Wrocławiu 2006; 156.
• Bittl JA, Storny J, Brinker JA et al.: for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764--69.
• Bush L: Argatroban a selective potent thrombin inhibitor. Cardiovasc Drug Rev 1991; 9: 247--63.
• Lewis BE, Matthai WH, Cohen M et al.: for the ARG -216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary investigation in patients with heparin - induced thrombocytopenia. Cathet Cardiovasc Intervent 2002; 57: 177--84.
• Wahlander K, Lapidus L, Olsson GG et al.: Pharmacokinetics, pharmcodynamics and clinical effects of the oral direct thromin inhibitor ximelagatran in acute treatment of patiens with pulmonary embolism and deep vein thrombosis. Thromb Res 2002; 107: 93--99.
• Eriksson BI, Bergqvist D, Kalebo P et al.: Melagatran for thrombin inhibition in orthopedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet 2002; 360: 1441--47.
• Potzsch B, Madlener K, Seelig C et al.: Monitoring of small r-hirudin anticoagulation during cardiopulmonary by-pass, assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920--25.

Identifiers

DOI

10.2478/v10035-009-0047-5